Cardiology Research Analysis
Q4 2025 in cardiology was defined by event-focused lipid therapeutics, immune–metabolic mechanisms, and quantitative frameworks that generalize across care settings. APOC3 antisense therapy achieved large triglyceride reductions with concomitant prevention of acute pancreatitis, while an oral PCSK9 inhibitor matched injectable LDL-C lowering and reduced Lp(a); evolocumab extended outcome benefits to high-risk primary prevention. Multi-omic studies of clonal hematopoiesis mapped causal inflammato